Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Discontinued Operations: 2020-2022

Historic Cash from Discontinued Operations for Theravance Biopharma (TBPH) over the last 3 years, with Dec 2022 value amounting to -$184.6 million.

  • Theravance Biopharma's Cash from Discontinued Operations fell 6455.40% to -$179.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$184.6 million, marking a year-over-year change of. This contributed to the annual value of -$184.6 million for FY2022, which is 761.12% down from last year.
  • Theravance Biopharma's Cash from Discontinued Operations amounted to -$184.6 million in FY2022, which was down 761.12% from $27.9 million recorded in FY2021.
  • Theravance Biopharma's 5-year Cash from Discontinued Operations high stood at $27.9 million for FY2021, and its period low was -$184.6 million during FY2022.
  • For the 3-year period, Theravance Biopharma's Cash from Discontinued Operations averaged around -$48.1 million, with its median value being $12.3 million (2020).
  • In the last 5 years, Theravance Biopharma's Cash from Discontinued Operations skyrocketed by 126.16% in 2021 and then tumbled by 761.12% in 2022.
  • Over the past 3 years, Theravance Biopharma's Cash from Discontinued Operations (Yearly) stood at $12.3 million in 2020, then surged by 126.16% to $27.9 million in 2021, then tumbled by 761.12% to -$184.6 million in 2022.